Intensive glucose control and cardiovascular disease in type 2 diabetes--should we change the recommended target for glycated hemoglobin? Commentary to ACCORD and ADVANCE trials.
Gaede
Peter
P
D001786:Blood Glucose / Q000187:drug effects*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006442:Glycated Hemoglobin / Q000032:analysis* / Q000187:drug effects / Q000592:standards*; D017408:Guidelines as Topic; D006801:Humans; D006973:Hypertension / Q000150:complications; D007003:Hypoglycemia / Q000139:chemically induced
D001786:Blood Glucose; D006442:Glycated Hemoglobin